Last reviewed · How we verify

Maxipime (Cefepime Hydrochloride)

Baxter · FDA-approved approved Small molecule Under review Quality 64/100

Maxipime (generic name: Cefepime Hydrochloride) is a Cephalosporin Small molecule drug developed by Baxter. It is currently FDA-approved (first approved 1996) for Bacterial infection due to Klebsiella pneumoniae, Bacterial peritonitis, Bacterial pneumonia.

Cefepime is a cephalosporin antibacterial drug that inhibits bacterial cell wall synthesis.

Maxipime, also known as Cefepime, is a fourth-generation cephalosporin antibiotic with an extended spectrum of activity against Gram-positive and Gram-negative bacteria. It has been studied in clinical trials for various conditions, including Gram-negative bacteremia, febrile neutropenia, and serious Gram-negative infections, among others.

At a glance

Generic nameCefepime Hydrochloride
SponsorBaxter
Drug classCephalosporin
TargetBacterial cell wall peptidoglycan
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved
First approval1996

Mechanism of action

Cefepime is a cephalosporin antibacterial drug belonging to the beta-lactam class of antibiotics. Cephalosporins work by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins and disrupting peptidoglycan cross-linking. This mechanism results in bacterial cell wall instability and cell death.

Approved indications

Common side effects

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Maxipime

What is Maxipime?

Maxipime (Cefepime Hydrochloride) is a Cephalosporin drug developed by Baxter, indicated for Bacterial infection due to Klebsiella pneumoniae, Bacterial peritonitis, Bacterial pneumonia.

How does Maxipime work?

Cefepime is a cephalosporin antibacterial drug that inhibits bacterial cell wall synthesis.

What is Maxipime used for?

Maxipime is indicated for Bacterial infection due to Klebsiella pneumoniae, Bacterial peritonitis, Bacterial pneumonia, Bacterial urinary infection, Complicated Bacteroides Peritonitis.

Who makes Maxipime?

Maxipime is developed and marketed by Baxter (see full Baxter pipeline at /company/baxter).

What is the generic name of Maxipime?

Cefepime Hydrochloride is the generic (nonproprietary) name of Maxipime.

What drug class is Maxipime in?

Maxipime belongs to the Cephalosporin class. See all Cephalosporin drugs at /class/cephalosporin.

When was Maxipime approved?

Maxipime was first approved on 1996.

What development phase is Maxipime in?

Maxipime is FDA-approved (marketed).

What are the side effects of Maxipime?

Common side effects of Maxipime include Any AEs with frequency less than 2%, Headache, Diarrhoea, Constipation, Hypertension, Nausea.

What does Maxipime target?

Maxipime targets Bacterial cell wall peptidoglycan and is a Cephalosporin.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing